Invex Therapeutics Ltd has released a press release.
Appendix 4D and Half-year Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
Later from Invex Therapeutics
- Exenatide Meets Key Endpoints in IIH Clinical Trial
- Succesful $26 million Share Placement
- Phase II Clinical Results and Capital Raising Presentation
- Notice of Allowance for Key US Exenatide Patent
- Initial FDA and EMA Advice on Presendin Development
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics